Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs next year. Despite the potential obstacles, Pfizer's long-term prospects are ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current position and recent performance. The stock’s slight rebound over the past month ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Pfizer's financial health is concerning, with unsustainable dividend ...

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months.

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...